{"id":20555,"date":"2024-07-08T04:30:00","date_gmt":"2024-07-08T08:30:00","guid":{"rendered":"https:\/\/dbv-technologies.com\/press_releases\/bilan-semestriel-du-contrat-de-liquidite-dbv-technologies-avec-oddo-bhf-11\/"},"modified":"2024-07-09T09:23:51","modified_gmt":"2024-07-09T13:23:51","slug":"bilan-semestriel-du-contrat-de-liquidite-dbv-technologies-avec-oddo-bhf-11","status":"publish","type":"press_releases","link":"https:\/\/dbv-technologies.com\/fr\/press_releases\/bilan-semestriel-du-contrat-de-liquidite-dbv-technologies-avec-oddo-bhf-11\/","title":{"rendered":"Bilan semestriel du contrat de liquidit\u00e9 DBV Technologies avec ODDO BHF"},"content":{"rendered":"<div class=\"pr-date-globe\">July 08, 2024 16:30 ET<\/div>\n<p align=\"right\"><strong>Informations R\u00e9glement\u00e9es<\/strong><br \/>Montrouge, France, le 8 juillet 2024<\/p>\n<p align=\"justify\"><strong>Bilan semestriel du contrat de liquidit\u00e9 DBV Technologies avec ODDO BHF<\/strong><\/p>\n<p align=\"justify\">DBV Technologies &lpar;Euronext : DBV \u2013 ISIN : FR0010417345 \u2013 Nasdaq : DBVT), laboratoire biopharmaceutique fran\u00e7ais, publie aujourd\u2019hui le bilan semestriel de son contrat de liquidit\u00e9 avec ODDO BHF.<\/p>\n<p align=\"justify\">Au titre du contrat de liquidit\u00e9 confi\u00e9 \u00e0 ODDO BHF, portant sur les actions de la soci\u00e9t\u00e9 DBV TECHNOLOGIES, \u00e0 la date du 30 juin 2024, les moyens suivants figuraient au compte de liquidit\u00e9 : <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify;\">303.744 titres DBV Technologies,&nbsp;<\/li>\n<li style=\"text-align:justify;\">62.415,60 euros. <\/li>\n<\/ul>\n<p align=\"justify\">Lors de la mise en place du contrat, \u00e0 compter du 1<sup>e<\/sup> juillet 2018, les moyens suivants figuraient au compte de liquidit\u00e9 : <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify;\">41. 159 titres DBV Technologies, <\/li>\n<li style=\"text-align:justify;\">432.367,25 euros. <\/li>\n<\/ul>\n<p align=\"justify\">Sur la p\u00e9riode du 01\/01\/2024 au 30\/06\/2024, ont \u00e9t\u00e9 ex\u00e9cut\u00e9es&nbsp;: <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify;\">912 transactions \u00e0 l\u2019achat,<\/li>\n<li style=\"text-align:justify;\">694 transactions \u00e0 la vente.<\/li>\n<\/ul>\n<p align=\"justify\">Sur cette m\u00eame p\u00e9riode, les volumes \u00e9chang\u00e9s ont repr\u00e9sent\u00e9&nbsp;:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify;\">299.986 titres et 397.966 euros \u00e0 l\u2019achat,<\/li>\n<li style=\"text-align:justify;\">219.230 titres et 310.114 euros \u00e0 la vente.<\/li>\n<\/ul>\n<p align=\"justify\"><strong>\u00c0 propos de DBV Technologies <\/strong><\/p>\n<p align=\"justify\">DBV Technologies est une entreprise biopharmaceutique de stade clinique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement d\u2019options de traitement des allergies alimentaires et autres affections immunologiques ayant d\u2019importants besoins m\u00e9dicaux non satisfaits. DBV Technologies se concentre actuellement sur l\u2019\u00e9tude de l\u2019utilisation de sa plateforme technologique exclusive, Viaskin\u2122, pour traiter les allergies alimentaires caus\u00e9es par une r\u00e9action immunitaire hypersensible et caract\u00e9ris\u00e9es par une gamme de sympt\u00f4mes dont la gravit\u00e9 varie de l\u00e9g\u00e8re \u00e0 l\u2019anaphylaxie potentiellement mortelle. Des millions de personnes vivent avec des allergies alimentaires, y compris de jeunes enfants. Gr\u00e2ce \u00e0 l\u2019immunoth\u00e9rapie \u00e9picutan\u00e9e &lpar;EPIT\u2122), la plateforme Viaskin est con\u00e7ue pour dispenser des quantit\u00e9s de microgrammes d\u2019un compos\u00e9 biologiquement actif dans le syst\u00e8me immunitaire \u00e0 travers une peau intacte. L\u2019EPIT est une nouvelle classe de traitement non invasif cherchant \u00e0 modifier l\u2019allergie sous-jacente d\u2019un individu en r\u00e9\u00e9duquant le syst\u00e8me immunitaire \u00e0 se d\u00e9sensibiliser \u00e0 l\u2019allerg\u00e8ne en tirant parti des propri\u00e9t\u00e9s de tol\u00e9rance immunitaire de la peau. DBV Technologies s\u2019est engag\u00e9e \u00e0 transformer le traitement des personnes souffrant d\u2019allergies alimentaires. Les programmes d\u2019allergie alimentaire de la Soci\u00e9t\u00e9 comprennent des \u00e9tudes cliniques en cours avec Viaskin Peanut chez les jeunes enfants &lpar;de 1 \u00e0 3 ans) et les enfants &lpar;de 4 \u00e0 7 ans) allergiques \u00e0 l\u2019arachide.<\/p>\n<p align=\"justify\">Le si\u00e8ge mondial de DBV Technologies est situ\u00e9 \u00e0 Ch\u00e2tillon, en France, avec des op\u00e9rations nord-am\u00e9ricaines bas\u00e9es \u00e0 Warren, dans le New Jersey. Les actions ordinaires de la Soci\u00e9t\u00e9 sont n\u00e9goci\u00e9es sur le segment B d\u2019Euronext Paris &lpar;symbole : DBV, code ISIN : FR0010417345) et les ADS de la Soci\u00e9t\u00e9 &lpar;chacun repr\u00e9sentant une action ordinaire) sont n\u00e9goci\u00e9s sur le Nasdaq Stock Market &lpar;symbole: DBVT\u2014 CUSIP: 23306J101).<\/p>\n<p align=\"justify\">Pour plus d\u2019informations, veuillez consulter&nbsp;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ny-Ra5EawvkXtGvJCWKfGxabX0VDJKw_FP3MEx05Bi0lmiJUUwSyy6vPZ0F0gq9kgv3l2-M82bPGzFltIsshKzAwM-3soa28kSN9Mvl516XPy4HeNqTYxFXoKfdj7nJC\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.dbv-technologies.com\">www.dbv-technologies.com<\/a> &nbsp;et nous contacter sur&nbsp;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=A5XEeTfqJwGPryrmvK-Rsy_LwDs3M-2oIFiSj4QzJ-yyILJxhXVEFmbrsoYylySKivbiMVMP8t0FU7X8kTqbThSYhPqYMZ8RTikO0yPxnUFC1deFv3OH--uj10bfONf70kwYQDk1NgeSbJ7N2BY2XbjnCbufCn2gu0U6QEFDBXPnpu_gL4SuO8BVfx_ls-A-p6B0Y1y_i42xZ9nLtxYFTaz7Nr8KiETiaqEIIgHGXGSa0gdxVTAUaEs7Niq7d7F6_7pw7MRDhUkzCS83e3AvaXrZjjdmudwJaen2YeZ6E1Q=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"X &lpar;anciennement Twitter)\">X &lpar;anciennement Twitter)<\/a>&nbsp;et&nbsp;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LbIZyXFvujhrHCnLUD_YkLGvgEelvRkwHGznBUFggEvsZvLL-SGSI3JbFTNPQ_NeBs3kfhfH1J8PXVRTaOtcCEihfj7z_eJcGKoSOGgEFoAQTqDxHxI1XPMEpzaeWI1EgZOZlcFRkLsX5JUUlJAhTPqDIQE-0K7t2pzEceSfUwyqbrfgekmHlO0NUJX_g6gMegKB108JDSjAWuMy-RAY4HjkdE_zOp6LXVnfT6mUVJEaxrMoxwBc4KNX1hxlK73DA52DLq8rS-7ubY-GxGqnAg==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"LinkedIn.\">LinkedIn.<\/a><\/p>\n<p align=\"justify\">Viaskin et EPIT sont des marques commerciales de DBV Technologies.<\/p>\n<p align=\"left\"><strong>Contact avec les investisseurs<\/strong><br \/>Katie Matthews<br \/>DBV Technologies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MoK6NLmoxnsmjSpn9nN7b4taeZEwumVXiiiczWFcfrt6VPuVstu_ExXuZX8KuO3_fsjS5R5RaKXbhuIBx5S3cF755R1QDBqJ_jstcbghkxjUAeiV9GilQ1vgzrxMVWMkOCg5ZdUwu9n0gkaNdv8z_g==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"katie.matthews@dbv-technologies.com\">katie.matthews@dbv-technologies.com<\/a><\/p>\n<p align=\"left\"><strong>Contact avec les m\u00e9dias<\/strong><br \/>Angela Marcucci<br \/>DBV Technologies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ESK6ri2qynUQ2yPucG9g2HDJT4W9WPQ6owwmEVC5I1TKHVqXcAI2mKN9zYtLpL-swGArgXxB0fDrVKzzZF_vJ1FqX4OwBR-7ijgMROFEeX-9n-LvCuk6pp8gronIEbY4dzdOk6RL9c0SgIXRvfGziw==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"angela.marcucci@dbv-technologies.com\">angela.marcucci@dbv-technologies.com<\/a><\/p>\n<p id=\"gnw_attachments_section-header\">    <strong>Pi\u00e8ce jointe<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=89ZewbAFKWJDAu2ynVavo69uuBhSprLFr18n2hHhFEd221OBR9p35AQSQc2VzVBodxacnkHROR_NAQ_Vl-MoH9osL5RkXD5cEfvl5tpgo6E3MWVrghZgk98pmOax2AKycjH7xN60toSn2oSabfF1x1JXBtRQpGAaWDy1dfl9CF4=\" title=\"version PDF\" rel=\"nofollow noopener\">version PDF<\/a>      <\/li>\n<\/ul>\n<p><img decoding=\"async\" data-src=\"https:\/\/ml-eu.globenewswire.com\/media\/NTI2ODIwZTYtMTM4OC00NDM1LWIyMjItNWQxN2UzZTM0YWE4LTEwMTExNTI=\/tiny\/DBV-Technologies-S-A-.png\" referrerpolicy=\"no-referrer-when-downgrade\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\">            <\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"wds_primary_press_release_type":0,"footnotes":""},"press_release_type":[47],"class_list":["post-20555","press_releases","type-press_releases","status-publish","hentry","press_release_type-amf-filing"],"acf":[],"_links":{"self":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/20555","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/types\/press_releases"}],"version-history":[{"count":0,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/20555\/revisions"}],"wp:attachment":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/media?parent=20555"}],"wp:term":[{"taxonomy":"press_release_type","embeddable":true,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_release_type?post=20555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}